	US 11,752,095 B2
	Medroxyprogesterone acetate injectable compositions and methods of use
Prakash Sundaramurthi, New Hope, PA (US); Ivana Mijakovac, Zagreb (HR); Andrea Rasic, Zagreb (HR); and Iva Tunjic, Zagreb (HR)
Assigned to Family Health International, Durham, NC (US)
Appl. No. 17/273,392
Filed by Family Health International, Durham, NC (US)
PCT Filed Sep. 6, 2019, PCT No. PCT/IB2019/057537 § 371(c)(1), (2) Date Mar. 4, 2021, PCT Pub. No. WO2020/049521, PCT Pub. Date Mar. 12, 2020.
Claims priority of provisional application 62/728,470, filed on Sep. 7, 2018.
Prior Publication US 2022/0105027 A1, Apr. 7, 2022
Int. Cl. A61K 9/00 (2006.01); A61K 31/255 (2006.01); A61K 31/566 (2006.01); A61K 47/02 (2006.01); A61K 47/10 (2017.01); A61K 47/20 (2006.01)

CPC A61K 9/0019 (2013.01) [A61K 31/255 (2013.01); A61K 31/566 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/20 (2013.01)]

22 Claims

1. An aqueous composition for subcutaneous injection comprising medroxyprogesterone acetate at a concentration of about 260 mg/ml to 440 mg/ml, docusate sodium at a concentration of about 0.6 mg/ml to 1.5 mg/ml, and polyethylene glycol.